Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
企業コードTRIB
会社名Trinity Biotech PLC
上場日Oct 21, 1992
最高経営責任者「CEO」Gillard (John)
従業員数- -
証券種類Depository Receipt
決算期末Oct 21
本社所在地Ida Business Park, Bray, Co Wicklow
都市DUBLIN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Ireland
郵便番号18
電話番号01135312955111
ウェブサイトhttps://www.trinitybiotech.com/
企業コードTRIB
上場日Oct 21, 1992
最高経営責任者「CEO」Gillard (John)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし